A Phase 3 interventional study of Vedolizumab in Colitis, Ulcerative, sponsored by Takeda. Completed at 65 sites in 14 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-04-30.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing vedolizumab in Colitis, Ulcerative — 5 open to participants now, 9 under way, 6 of them phase 3. vedolizumab · Colitis, Ulcerative.
Among the 38 studies testing vedolizumab in Colitis, Ulcerative, this one is the 18th largest by enrollment, is one of 5 that started in 2021, is one of 14 in phase 3, and was the 27th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →5 of the 38 studies testing vedolizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:
Takeda · Sites in United States, Belgium, Bulgaria and 11 more countries
Ages 2–17
Takeda · Sites in United States
Ages 18–80
Takeda · Sites in United States, Belgium, Bulgaria and 13 more countries
Ages 2–17
Takeda · Sites in United States, Australia, Belgium and 15 more countries
Ages 2+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 121 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 110 across the 38 interventional studies. Of the 23 that completed or were terminated, 16 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 38 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
68 studies in Colitis, Ulcerative by Takeda: 6 open now, 10 under way, 5 of them phase 3. Of 54 finished, 35 (65%) have results posted.
Among the 68 studies in Colitis, Ulcerative by Takeda, this one is the 27th largest by enrollment of the 43 interventional ones that give a count, is one of 9 that started in 2021, is one of 21 in phase 3, and was the 47th registered.
Takeda’s Colitis, Ulcerative studies by the year they started, since 2003.
4 of the studies testing vedolizumab in Colitis, Ulcerative that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06880744Phase 3AbbVieA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | 2027-08 |
| NCT03221036Phase 3TakedaEfficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis | 2027-09-24 |
| NCT06581328TakedaA Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting | 2027-05-01 |
| NCT06095128TakedaA Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) | 2027-07-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 38 studies testing vedolizumab in Colitis, Ulcerative, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 68 in Colitis, Ulcerative:
This tab as a report to print or save as PDF → With an account.
Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system. In this study, children and teenagers with moderate to severe ulcerative colitis will be treated with vedolizumab.
The main aim of the study is to check if participants achieve remission after treatment with vedolizumab. Remission means symptoms improve or disappear and an endoscopy shows no or limited signs of disease.
The study is also evaluating side effects of vedolizumab in the children and teenager with moderately to severely active ulcerative colitis.
Participants will receive 3 infusions of vedolizumab over 6 weeks. Then, those who have a clinical response will receive 1 of 3 doses of vedolizumab once every 8 weeks. They will receive the same dose every time.
The drug being tested in this study is called vedolizumab. Vedolizumab is being tested to treat pediatric participants who have moderately to severely active UC. Participants to be enrolled must have failed response to, lost response to, or been intolerant to at least 1 of the current standard of care (SOC) induction and maintenance therapies for UC including immunomodulators (eg, azathioprine [AZA], 6-mercaptopurine [6-MP], methotrexate [MTX]), and tumor necrosis factor-alpha (TNF-α) antagonists (eg, infliximab, adalimumab).
The study will enroll approximately 120 patients.
During the Induction Period participants will receive 3 doses of vedolizumab IV infusion at Day 1, Week 2, and Week 6 based on their weight at Baseline:
At Week 14, participants who achieve clinical response will be randomly assigned (by chance, like flipping a coin) in a 1:1 ratio to one of the 2 double-blind dose groups (high dose and low dose), stratified by previous exposure/failure to TNF-α antagonists therapy or naive to TNF-α antagonists therapy, and weight. Participants will receive vedolizumab IV infusions every 8 weeks (Q8W) up to Week 46 during the Maintenance Period as follows:
The dose will remain blinded to the participant and study doctor and staff during the study (unless there is an urgent medical need). All participants will be administered vedolizumab via IV infusion. In participants who demonstrate lack of maintenance of clinical response during the Maintenance Period the dose will be escalated in a blinded fashion based on the weight at the time of the worsening of disease. In addition one-time rescue therapy with corticosteroids is allowed during Maintenance period.
This multi-center trial will be conducted worldwide. After the Week 54 visit, participants who are younger than 18 years may be eligible to continue receiving vedolizumab in extension study MLN0002-3029 (NCT05442567). Participants who do not maintain corticosteroid-free clinical response at Week 54 or who discontinue study drug at any time during the induction or maintenance periods of this study will undergo an end of study (EOS) or early termination (ET) visit, as well as a safety visit 18 weeks after the last dose of vedolizumab, in addition these participants would enter study MLN0002-3029 for an observational long-term follow-up (LTFU) period of 2 years after the last dose of study drug in the current study. During the LTFU period, data will be collected either by clinic visit OR, if site attendance is not feasible, by phone call every 6 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participant with active or latent tuberculosis (TB), as evidenced by a diagnostic TB test performed within 30 days of screening or during the screening period that is positive, defined as:
Participants with evidence of positive surface antigen (HBsAg) or hepatitis B core antibody (HBcAb). Hepatitis B virus (HBV) immune participants (ie, hepatitis B surface antigen [HBsAg]-negative and hepatitis B antibody-positive) may, however, be included. Note: If a participant tests negative for HBsAg, but positive for HBcAb, the participant would be considered eligible if the absence of HBV DNA is confirmed by HBV DNA polymerase chain reaction reflex testing performed in the central laboratory.
Participants with chronic virus (HCV) (ie, positive HCV antibody [HCVAb] and HCV RNA). Note: Subjects who are HCVAb-positive without evidence of HCV RNA may be considered eligible (spontaneous viral clearance or previously treated and cured [defined as no evidence of HCV RNA at least 12 weeks before baseline]).
Other inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vedolizumab 300 mg, intravenous (IV) infusion, at Day 1, Weeks 2 and 6 in the Induction Period. Participants with UC having Baseline weight of ≥30 kg are included in this arm.
Drug: Vedolizumab
Vedolizumab 200 mg, IV infusion, at Day 1, Weeks 2 and 6 in the Induction Period. Participants with UC having Baseline weight of \>15 to \<30 kg are included in this arm.
Drug: Vedolizumab
Vedolizumab 150 mg, IV infusion, at Day 1, Weeks 2 and 6 in the Induction Period. Participants with UC having Baseline weight of 10 to 15 kg are included in this arm.
Drug: Vedolizumab
Vedolizumab 300 mg, IV infusion, once every 8 weeks (Q8W) from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of ≥30 kg who achieved clinical response at Week 14 randomized to this high dose arm group will receive vedolizumab 300 mg.
Drug: Vedolizumab
Vedolizumab 150 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of ≥30 kg who achieved clinical response at Week 14 randomized to this low dose arm group will receive vedolizumab 150 mg.
Drug: Vedolizumab
Vedolizumab 200 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of \>15 to \<30 kg who achieved clinical response at Week 14 randomized to this high dose arm group will receive vedolizumab 200 mg.
Drug: Vedolizumab
Vedolizumab 100 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of \>15 to \<30 kg who achieved clinical response at Week 14 randomized to this low dose arm group will receive vedolizumab 100 mg.
Drug: Vedolizumab
Vedolizumab 150 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of 10 to 15 kg who achieved clinical response at Week 14 randomized to this high dose arm group will receive vedolizumab 150 mg.
Drug: Vedolizumab
Vedolizumab 100 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of 10 to 15 kg who achieved clinical response at Week 14 randomized to this low dose arm group will receive vedolizumab 100 mg.
Drug: Vedolizumab
Vedolizumab IV infusion.
Also known as: MLN0002, ENTYVIO, KYNTELES
Percentage of Participants With Clinical Remission at Week 54 Based on Modified Mayo Score
Clinical remission based on the modified Mayo score was defined as stool frequency sub score 0 to 1 and a decrease of 1 or more from baseline, rectal bleeding sub score of 0, and endoscopy sub score 0 to 1 (modified so that a score of 1 does not include friability) and without presence of any intercurrent event. Mayo score was an instrument designed to measure disease activity of UC. Modified Mayo score was a composite index of 3 disease activity variables (stool frequency, rectal bleeding, and endoscopy). Each subscale was graded from 0 to 3 where higher score indicated more severe disease. These scores were summed to give a total score range of 0 to 9 where, higher score indicated more severe disease.
Time frame: At Week 54
Percentage of Participants With Clinical Remission at Week 14 Based on Modified Mayo Score
Clinical remission based on the modified Mayo score was defined as stool frequency sub score 0 to 1 and a decrease of 1 or more from baseline, rectal bleeding sub score of 0, and endoscopy sub score 0 to 1 (modified so that a score of 1 does not include friability) and without presence of any intercurrent event. Mayo score was an instrument designed to measure disease activity of UC. Modified Mayo score was a composite index of 3 disease activity variables (stool frequency, rectal bleeding, and endoscopy. Each subscale was graded from 0 to 3 where higher score indicated more severe disease. These scores were summed to give a total score range of 0 to 9 where, higher score indicated more severe disease.
Time frame: At Week 14
Percentage of Participants With Sustained Clinical Remission at Week 54 Based on Modified Mayo Score
Participants who had clinical remission at Week 14 were analyzed for sustained clinical remission at Week 54. Clinical remission based on the modified Mayo score was defined as stool frequency sub score 0 to 1 and a decrease of 1 or more from baseline, rectal bleeding sub score of 0, and endoscopy sub score 0 to 1 (modified so that a score of 1 does not include friability) and without presence of any intercurrent event. Mayo score was an instrument designed to measure disease activity of UC. Modified Mayo score was a composite index of 3 disease activity variables (stool frequency, rectal bleeding, and endoscopy. Each subscale was graded from 0 to 3 where higher score indicated more severe disease. These scores were summed to give a total score range of 0 to 9 where, higher score indicated more severe disease.
Time frame: At Week 54
Percentage of Participants With Sustained Endoscopic Remission at Week 54
Participants who had endoscopic remission at Week 14 were analyzed for sustained endoscopic remission at Week 54. Mayo endoscopic sub score (MES) was a subscale of the Mayo score, an instrument designed to measure disease activity of UC. The subscale was graded from 0 to 3 based on the findings on endoscopy where 0=normal or inactive disease, 1=mild disease (erythema, decreased vascular pattern), 2=moderate disease (marked erythema, lack of vascular pattern, friability, erosions), 3=severe disease (spontaneous bleeding, ulceration). Higher score indicated more severe disease.
Time frame: At Week 54
Percentage of Participants With Endoscopic Response at Week 14
Endoscopic response was defined as a decrease from baseline in the MES \>=1 point. MES was a subscale of the Mayo score, an instrument designed to measure disease activity of UC. The subscale was graded from 0 to 3 based on the findings on endoscopy where 0=normal or inactive disease, 1=mild disease (erythema, decreased vascular pattern), 2=moderate disease (marked erythema, lack of vascular pattern, friability, erosions), 3=severe disease (spontaneous bleeding, ulceration). Higher score indicated more severe disease.
Time frame: At Week 14
Percentage of Participants With Endoscopic Response at Week 54
Endoscopic response was defined as a decrease from baseline in the MES \>=1 point. MES was a subscale of the Mayo score, an instrument designed to measure disease activity of UC. The subscale was graded from 0 to 3 based on the findings on endoscopy where 0=normal or inactive disease, 1=mild disease (erythema, decreased vascular pattern), 2=moderate disease (marked erythema, lack of vascular pattern, friability, erosions), 3=severe disease (spontaneous bleeding, ulceration). Higher score indicated more severe disease.
Time frame: At Week 54
Percentage of Participants With Corticosteroid-free Clinical Remission at Week 54
Corticosteroid-free clinical remission based on the modified Mayo score was defined as when a participant meets the definition described in the primary endpoint and was off corticosteroids at least 12 weeks prior to and at Week 54 and without presence of any intercurrent event. Modified Mayo score was a composite index of 3 disease activity variables (stool frequency, rectal bleeding, and endoscopy. Each subscale was graded from 0 to 3 where higher score indicated more severe disease. These scores were summed to give a total score range of 0 to 9 where, higher score indicated more severe disease.
Time frame: At Week 54
Percentage of Participants With Clinical Remission at Week 54 Based on Complete Mayo Score
Clinical remission based on complete Mayo score was a score (inclusive of physician global assessment \[PGA\]) of \<=2 points with no individual sub score \>1 and without presence of any intercurrent event. Mayo score was an instrument designed to measure disease activity of UC. Complete Mayo score was a composite index of 4 disease activity variables (stool frequency, rectal bleeding, endoscopy \[modified so that a score of 1 does not include friability\], and PGA sub scores) ranging from 0-12. Higher score indicated more severe disease.
Time frame: At Week 54
Serum Trough Concentrations of Vedolizumab Over Time
Serum trough concentration of vedolizumab was reported.
Time frame: Predose at Week 14 and post dose at Week 54
Percentage of Participants With Positive Anti-vedolizumab Antibodies (AVA)
AVA positive was defined as a confirmed AVA positive result.
Time frame: Up to Week 54
Percentage of Participants With Positive Neutralizing AVA
Positive Neutralizing AVA was defined as a positive result in the neutralizing AVA assay at any visit.
Time frame: Up to Week 54
Percentage of Participants With Sustained Clinical Response at Week 54 Based on Complete Mayo Score
Participants who had clinical response at Week 14 were analyzed for sustained clinical response at Week 54. Sustained refers to meeting the specific endpoint criteria at both Week 14 and Week 54. Sustained clinical response is defined as meeting the following criteria at both Week 14 and Week 54: reduction in complete Mayo score of \>=3 points and \>=30% from baseline with an accompanying decrease in rectal bleeding sub score of \>=1 point or absolute rectal bleeding sub score of \<=1 point. Mayo score was an instrument designed to measure disease activity of UC. Complete Mayo score was a composite index of 4 disease activity variables (stool frequency, rectal bleeding, endoscopy \[modified so that a score of 1 does not include friability\], and PGA sub scores) ranging from 0-12. Higher score indicated more severe disease.
Time frame: At Week 54
Percentage of Participants With Clinical Response up to Week 54 Based on Partial Mayo Score
Clinical response was where a participant achieved clinical response if they had a reduction of \>=2 points and \>=25% from the baseline partial Mayo score, including a \>=1 point decrease in the Mayo stool frequency sub score and a \>=1 point reduction in the rectal bleeding sub score or absolute rectal bleeding sub score of \<=1 point. Mayo score was an instrument designed to measure disease activity of UC. A partial Mayo score was defined as composite index of 3 disease activity variables (stool frequency, rectal bleeding, and PGA sub scores) that ranged from 0-9 and excluded the endoscopy sub score. Higher score indicates more severe disease.
Time frame: At Weeks 2, 6, 10, 14, 22, 30, 38, 46, and 54
Percentage of Participants With Clinical Remission up to Week 54 Based on Partial Mayo Score
Clinical remission based on partial Mayo score was defined as a partial Mayo score of \<=2 points and no individual sub score \>1 point. Mayo score was an instrument designed to measure disease activity of UC. A partial Mayo score was defined as composite index of 3 disease activity variables (stool frequency, rectal bleeding, and PGA sub scores) that ranged from 0-9 and excluded the endoscopy sub score. Higher score indicates more severe disease.
Time frame: At Weeks 2, 6, 10, 14, 22, 30, 38, 46, and 54
Percentage of Participants With at Least One Treatment Emergent Adverse Event (TEAE), Treatment Emergent Serious Adverse Event (TESAE), and Adverse Event of Special Interest (AESI)
A TEAE was defined as an AE whose date of onset occurred on or after the first dose of study drug through Week 54 for participants entering the extension study or the final safety visit 18 weeks after their last dose of study drug for those who do not enter the extension study or those who early terminate. A TESAE was defined as an undesirable event that was not present prior to medical treatment or an already present event that worsened either in intensity or frequency following the first dose of study drug, that occurred from the first dose of study drug to the day of last dose of study drug + 126 days. AESI was defined as an AE (serious or nonserious) of medical concern specific to the compound or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor was appropriate. AESIs include infusion-related reactions and hypersensitivity, serious infection, malignancy, or other (liver injury and progressive multifocal leukoencephalopathy \[PML\]).
Time frame: From first dose of study drug up to end of follow up (up to 3.7 years)
Change From Baseline in Weight
Change from baseline in weight was reported.
Time frame: At Weeks 2, 6, 10, 14, 22, 30, 38, 46, and 54
Change From Baseline in Weight Z-score
Change from baseline in weight Z-score was reported. Weight z-score expresses how an individual's measured weight compares to the expected weight of a reference population of the same age and sex, standardized using population growth charts. It represents the number of standard deviations (SDs) an individual's weight is above or below the mean of the reference population. Z-score was calculated as: Z-score = (observed value - median value of the reference population) / standard deviation value of reference population. A Z-score of 0 represents the mean of the reference population. A negative Z-score indicates that the observed value is below (lower than) the reference mean, while a positive Z-score indicates that the observed value is above (higher than) the reference mean.
Time frame: At Weeks 2, 6, 10, 14, 22, 30, 38, 46, and 54
Change From Baseline in Height
Change from baseline in height was reported.
Time frame: At Weeks 2, 6, 10, 14, 22, 30, 38, 46, and 54
Change From Baseline in Linear Growth Z-score
Change from baseline in linear growth Z-score were reported. Linear growth Z-score is a standardized measure that describes how far a measured height deviates from the median height of a reference population of the same age and sex based on established growth charts. It is expressed in units of standard deviations (SD). Z-score was calculated as: Z-score = (observed value - median value of the reference population) / standard deviation value of reference population. A Z-score of 0 represents the mean of the reference population. A negative Z-score indicates that the observed value is below (lower than) the reference mean, while a positive Z-score indicates that the observed value is above (higher than) the reference mean.
Time frame: At Weeks 2, 6, 10, 14, 22, 30, 38, 46, and 54
Number of Participants With Change From Baseline in Tanner Stage at Week 54
Tanner stages are used to evaluate growth parameters. They are standardized for age, sex, and pubertal development, with Stage 1 representing the prepubertal stage and Stage 5 representing the fully mature adult stage. It measures Female pubertal development staged by pubic hair development and breast size; male pubertal development staged by size of the genitalia and development of pubic hair. Rated in 5 stages: stage 1 (no development) to 5 (adult-like development in quantity and size). The data reported shows shifts in participants' Tanner stages from baseline to Week 54.
Time frame: At Week 54
The study was conducted across 43 investigative sites in the United States, Asia/Australia, Europe, and Israel from 19 October 2021 to 1 July 2025.
| Milestone | Participants 10 to 15 kg: Vedolizumab 150 mg | Participants >15 to <30 kg: Vedolizumab 200 mg | Participants >=30 kg: Vedolizumab 300 mg | Participants With All Weight Groups Combined: Vedolizumab Low Dose | Participants With All Weight Groups Combined: Vedolizumab High Dose |
|---|---|---|---|---|---|
| Started | 3 | 27 | 91 | 0 | 0 |
| Switched weight group from 10-15kg to >15kg to <30kg weight | 1 | 0 | 0 | 0 | 0 |
| Switched weight group from >15 to <30kg to >=30kg weight group | 0 | 4 | 0 | 0 | 0 |
| Treated | 3 | 27 | 90 | 0 | 0 |
| Completed | 2 | 21 | 70 | 0 | 0 |
| Not completed | 1 | 6 | 21 | 0 | 0 |
| Withdrew: Adverse event | 0 | 2 | 2 | 0 | 0 |
| Withdrew: Failure to meet continuation criteria | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 4 | 15 | 0 | 0 |
| Withdrew: Withdrawal by parent/guardian | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Other | 1 | 0 | 1 | 0 | 0 |
| Milestone | Participants 10 to 15 kg: Vedolizumab 150 mg | Participants >15 to <30 kg: Vedolizumab 200 mg | Participants >=30 kg: Vedolizumab 300 mg | Participants With All Weight Groups Combined: Vedolizumab Low Dose | Participants With All Weight Groups Combined: Vedolizumab High Dose |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 47 | 46 |
| Completed | 0 | 0 | 0 | 43 | 31 |
| Not completed | 0 | 0 | 0 | 4 | 15 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 1 | 4 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 2 | 6 |
| Withdrew: Withdrawal by parent/guardian | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Failure to meet continuation criteria | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Protocol deviation | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 1 |
Clinical remission based on the modified Mayo score was defined as stool frequency sub score 0 to 1 and a decrease of 1 or more from baseline, rectal bleeding sub score of 0, and endoscopy sub score 0 to 1 (modified so that a score of 1 does not include friability) and without presence of any intercurrent event. Mayo score was an instrument designed to measure disease activity of UC. Modified Mayo score was a composite index of 3 disease activity variables (stool frequency, rectal bleeding, and endoscopy). Each subscale was graded from 0 to 3 where higher score indicated more severe disease. These scores were summed to give a total score range of 0 to 9 where, higher score indicated more severe disease.
| percentage of participants | Participants With All Weight Groups Combined: Vedolizumab Low Dose | Participants With All Weight Groups Combined: Vedolizumab High Dose |
|---|---|---|
| Percentage of Participants With Clinical Remission at Week 54 Based on Modified Mayo Score | 51.1 (36.1 to 65.9) | 43.5 (28.9 to 58.9) |
Clinical remission based on the modified Mayo score was defined as stool frequency sub score 0 to 1 and a decrease of 1 or more from baseline, rectal bleeding sub score of 0, and endoscopy sub score 0 to 1 (modified so that a score of 1 does not include friability) and without presence of any intercurrent event. Mayo score was an instrument designed to measure disease activity of UC. Modified Mayo score was a composite index of 3 disease activity variables (stool frequency, rectal bleeding, and endoscopy. Each subscale was graded from 0 to 3 where higher score indicated more severe disease. These scores were summed to give a total score range of 0 to 9 where, higher score indicated more severe disease.
| percentage of participants | Participants 10 to 15 kg: Vedolizumab 150 mg | Participants >15 to <30 kg: Vedolizumab 200 mg | Participants >=30 kg: Vedolizumab 300 mg |
|---|---|---|---|
| Percentage of Participants With Clinical Remission at Week 14 Based on Modified Mayo Score | 33.3 (0.8 to 90.6) | 44.4 (25.5 to 64.7) | 31.9 (22.5 to 42.5) |
Participants who had clinical remission at Week 14 were analyzed for sustained clinical remission at Week 54. Clinical remission based on the modified Mayo score was defined as stool frequency sub score 0 to 1 and a decrease of 1 or more from baseline, rectal bleeding sub score of 0, and endoscopy sub score 0 to 1 (modified so that a score of 1 does not include friability) and without presence of any intercurrent event. Mayo score was an instrument designed to measure disease activity of UC. Modified Mayo score was a composite index of 3 disease activity variables (stool frequency, rectal bleeding, and endoscopy. Each subscale was graded from 0 to 3 where higher score indicated more severe disease. These scores were summed to give a total score range of 0 to 9 where, higher score indicated more severe disease.
| percentage of participants | Participants With All Weight Groups Combined: Vedolizumab Low Dose | Participants With All Weight Groups Combined: Vedolizumab High Dose |
|---|---|---|
| Percentage of Participants With Sustained Clinical Remission at Week 54 Based on Modified Mayo Score | 29.8 (17.3 to 44.9) | 28.3 (16.0 to 43.5) |
Participants who had endoscopic remission at Week 14 were analyzed for sustained endoscopic remission at Week 54. Mayo endoscopic sub score (MES) was a subscale of the Mayo score, an instrument designed to measure disease activity of UC. The subscale was graded from 0 to 3 based on the findings on endoscopy where 0=normal or inactive disease, 1=mild disease (erythema, decreased vascular pattern), 2=moderate disease (marked erythema, lack of vascular pattern, friability, erosions), 3=severe disease (spontaneous bleeding, ulceration). Higher score indicated more severe disease.
| percentage of participants | Participants With All Weight Groups Combined: Vedolizumab Low Dose | Participants With All Weight Groups Combined: Vedolizumab High Dose |
|---|---|---|
| Percentage of Participants With Sustained Endoscopic Remission at Week 54 | 36.2 (22.7 to 51.5) | 30.4 (17.7 to 45.8) |
Endoscopic response was defined as a decrease from baseline in the MES \>=1 point. MES was a subscale of the Mayo score, an instrument designed to measure disease activity of UC. The subscale was graded from 0 to 3 based on the findings on endoscopy where 0=normal or inactive disease, 1=mild disease (erythema, decreased vascular pattern), 2=moderate disease (marked erythema, lack of vascular pattern, friability, erosions), 3=severe disease (spontaneous bleeding, ulceration). Higher score indicated more severe disease.
| percentage of participants | Participants 10 to 15 kg: Vedolizumab 150 mg | Participants >15 to <30 kg: Vedolizumab 200 mg | Participants >=30 kg: Vedolizumab 300 mg |
|---|---|---|---|
| Percentage of Participants With Endoscopic Response at Week 14 | 66.7 (9.4 to 99.2) | 48.1 (28.7 to 68.1) | 49.5 (38.8 to 60.1) |
Endoscopic response was defined as a decrease from baseline in the MES \>=1 point. MES was a subscale of the Mayo score, an instrument designed to measure disease activity of UC. The subscale was graded from 0 to 3 based on the findings on endoscopy where 0=normal or inactive disease, 1=mild disease (erythema, decreased vascular pattern), 2=moderate disease (marked erythema, lack of vascular pattern, friability, erosions), 3=severe disease (spontaneous bleeding, ulceration). Higher score indicated more severe disease.
| percentage of participants | Participants With All Weight Groups Combined: Vedolizumab Low Dose | Participants With All Weight Groups Combined: Vedolizumab High Dose |
|---|---|---|
| Percentage of Participants With Endoscopic Response at Week 54 | 59.6 (44.3 to 73.6) | 47.8 (32.9 to 63.1) |
Corticosteroid-free clinical remission based on the modified Mayo score was defined as when a participant meets the definition described in the primary endpoint and was off corticosteroids at least 12 weeks prior to and at Week 54 and without presence of any intercurrent event. Modified Mayo score was a composite index of 3 disease activity variables (stool frequency, rectal bleeding, and endoscopy. Each subscale was graded from 0 to 3 where higher score indicated more severe disease. These scores were summed to give a total score range of 0 to 9 where, higher score indicated more severe disease.
| percentage of participants | Participants With All Weight Groups Combined: Vedolizumab Low Dose | Participants With All Weight Groups Combined: Vedolizumab High Dose |
|---|---|---|
| Percentage of Participants With Corticosteroid-free Clinical Remission at Week 54 | 56.5 (34.5 to 76.8) | 27.8 (9.7 to 53.5) |
Clinical remission based on complete Mayo score was a score (inclusive of physician global assessment \[PGA\]) of \<=2 points with no individual sub score \>1 and without presence of any intercurrent event. Mayo score was an instrument designed to measure disease activity of UC. Complete Mayo score was a composite index of 4 disease activity variables (stool frequency, rectal bleeding, endoscopy \[modified so that a score of 1 does not include friability\], and PGA sub scores) ranging from 0-12. Higher score indicated more severe disease.
| percentage of participants | Participants With All Weight Groups Combined: Vedolizumab Low Dose | Participants With All Weight Groups Combined: Vedolizumab High Dose |
|---|---|---|
| Percentage of Participants With Clinical Remission at Week 54 Based on Complete Mayo Score | 53.2 (38.1 to 67.9) | 43.5 (28.9 to 58.9) |
Serum trough concentration of vedolizumab was reported.
| microgram/ml (mcg/ml) | Participants With All Weight Groups Combined: Vedolizumab Low Dose | Participants With All Weight Groups Combined: Vedolizumab High Dose |
|---|---|---|
| At Week 14 | 16.92 ± 10.275 | 13.26 ± 9.522 |
| At Week 54 | 5.97 ± 4.120 | 12.60 ± 7.413 |
AVA positive was defined as a confirmed AVA positive result.
| percentage of participants | Participants With All Weight Groups Combined: Vedolizumab Low Dose | Participants With All Weight Groups Combined: Vedolizumab High Dose |
|---|---|---|
| Percentage of Participants With Positive Anti-vedolizumab Antibodies (AVA) | 2.3 | 6.5 |
Positive Neutralizing AVA was defined as a positive result in the neutralizing AVA assay at any visit.
| percentage of participants | Participants With All Weight Groups Combined: Vedolizumab Low Dose | Participants With All Weight Groups Combined: Vedolizumab High Dose |
|---|---|---|
| Percentage of Participants With Positive Neutralizing AVA | 0 | 2.2 |
Participants who had clinical response at Week 14 were analyzed for sustained clinical response at Week 54. Sustained refers to meeting the specific endpoint criteria at both Week 14 and Week 54. Sustained clinical response is defined as meeting the following criteria at both Week 14 and Week 54: reduction in complete Mayo score of \>=3 points and \>=30% from baseline with an accompanying decrease in rectal bleeding sub score of \>=1 point or absolute rectal bleeding sub score of \<=1 point. Mayo score was an instrument designed to measure disease activity of UC. Complete Mayo score was a composite index of 4 disease activity variables (stool frequency, rectal bleeding, endoscopy \[modified so that a score of 1 does not include friability\], and PGA sub scores) ranging from 0-12. Higher score indicated more severe disease.
| percentage of participants | Participants With All Weight Groups Combined: Vedolizumab Low Dose | Participants With All Weight Groups Combined: Vedolizumab High Dose |
|---|---|---|
| Percentage of Participants With Sustained Clinical Response at Week 54 Based on Complete Mayo Score | 66.0 (50.7 to 79.1) | 63.0 (47.5 to 76.8) |
Clinical response was where a participant achieved clinical response if they had a reduction of \>=2 points and \>=25% from the baseline partial Mayo score, including a \>=1 point decrease in the Mayo stool frequency sub score and a \>=1 point reduction in the rectal bleeding sub score or absolute rectal bleeding sub score of \<=1 point. Mayo score was an instrument designed to measure disease activity of UC. A partial Mayo score was defined as composite index of 3 disease activity variables (stool frequency, rectal bleeding, and PGA sub scores) that ranged from 0-9 and excluded the endoscopy sub score. Higher score indicates more severe disease.
| percentage of participants | Participants 10 to 15 kg: Vedolizumab 150 mg | Participants >15 to <30 kg: Vedolizumab 200 mg | Participants >=30 kg: Vedolizumab 300 mg |
|---|---|---|---|
| At Week 2 | 66.7 (9.4 to 99.2) | 37.0 (19.4 to 57.6) | 39.6 (29.5 to 50.4) |
| At Week 6 | 66.7 (9.4 to 99.2) | 70.4 (49.8 to 86.2) | 61.5 (50.8 to 71.6) |
| At Week 10 | 66.7 (9.4 to 99.2) | 77.8 (57.7 to 91.4) | 64.8 (54.1 to 74.6) |
| At Week 14 | 100 (29.2 to 100) | 77.8 (57.7 to 91.4) | 72.5 (62.2 to 81.4) |
| At Week 22 | 33.3 (0.8 to 90.6) | 59.3 (38.8 to 77.6) | 60.4 (49.6 to 70.5) |
| At Week 30 | 0.0 (0.0 to 70.8) | 74.1 (53.7 to 88.9) | 59.3 (48.5 to 69.5) |
| At Week 38 | 33.3 (0.8 to 90.6) | 63.0 (42.4 to 80.6) | 58.2 (47.4 to 68.5) |
| At Week 46 | 33.3 (0.8 to 90.6) | 70.4 (49.8 to 86.2) | 56.0 (45.2 to 66.4) |
| At Week 54 | 33.3 (0.8 to 90.6) | 70.4 (49.8 to 86.2) | 57.1 (46.3 to 67.5) |
Clinical remission based on partial Mayo score was defined as a partial Mayo score of \<=2 points and no individual sub score \>1 point. Mayo score was an instrument designed to measure disease activity of UC. A partial Mayo score was defined as composite index of 3 disease activity variables (stool frequency, rectal bleeding, and PGA sub scores) that ranged from 0-9 and excluded the endoscopy sub score. Higher score indicates more severe disease.
| percentage of participants | Participants 10 to 15 kg: Vedolizumab 150 mg | Participants >15 to <30 kg: Vedolizumab 200 mg | Participants >=30 kg: Vedolizumab 300 mg |
|---|---|---|---|
| At Week 2 | 33.3 (0.8 to 90.6) | 29.6 (13.8 to 50.2) | 23.1 (14.9 to 33.1) |
| At Week 6 | 66.7 (9.4 to 99.2) | 59.3 (38.8 to 77.6) | 48.4 (37.7 to 59.1) |
| At Week 10 | 66.7 (9.4 to 99.2) | 55.6 (35.3 to 74.5) | 59.3 (48.5 to 69.5) |
| At Week 14 | 66.7 (9.4 to 99.2) | 77.8 (57.7 to 91.4) | 65.9 (55.3 to 75.5) |
| At Week 22 | 33.3 (0.8 to 90.6) | 59.3 (38.8 to 77.6) | 58.2 (47.4 to 68.5) |
| At Week 30 | 0.0 (0.0 to 70.8) | 70.4 (49.8 to 86.2) | 61.5 (50.8 to 71.6) |
| At Week 38 | 33.3 (0.8 to 90.6) | 70.4 (49.8 to 86.2) | 60.4 (49.6 to 70.5) |
| At Week 46 | 33.3 (0.8 to 90.6) | 74.1 (53.7 to 88.9) | 58.2 (47.4 to 68.5) |
| At Week 54 | 33.3 (0.8 to 90.6) | 66.7 (46.0 to 83.5) | 53.8 (43.1 to 64.4) |
A TEAE was defined as an AE whose date of onset occurred on or after the first dose of study drug through Week 54 for participants entering the extension study or the final safety visit 18 weeks after their last dose of study drug for those who do not enter the extension study or those who early terminate. A TESAE was defined as an undesirable event that was not present prior to medical treatment or an already present event that worsened either in intensity or frequency following the first dose of study drug, that occurred from the first dose of study drug to the day of last dose of study drug + 126 days. AESI was defined as an AE (serious or nonserious) of medical concern specific to the compound or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor was appropriate. AESIs include infusion-related reactions and hypersensitivity, serious infection, malignancy, or other (liver injury and progressive multifocal leukoencephalopathy \[PML\]).
| percentage of participants | Participants 10 to 15 kg: Vedolizumab 150 mg | Participants >15 to <30 kg: Vedolizumab 200 mg | Participants >=30 kg: Vedolizumab 300 mg | Participants With All Weight Groups Combined: Vedolizumab Low Dose | Participants With All Weight Groups Combined: Vedolizumab High Dose |
|---|---|---|---|---|---|
| Participants with at Least One TEAE | 100 | 77.8 | 66.7 | 72.3 | 63.0 |
| Participants with TESAE | 0 | 14.8 | 10.0 | 6.4 | 10.9 |
| Participants with AESI | 0 | 25.9 | 12.2 | 10.6 | 19.6 |
Change from baseline in weight was reported.
| kilograms (kg) | Participants With All Weight Groups Combined: Vedolizumab Low Dose | Participants With All Weight Groups Combined: Vedolizumab High Dose |
|---|---|---|
| Change at Week 2 | 0.50 ± 1.287 | 0.74 ± 1.037 |
| Change at Week 6 | 1.04 ± 2.050 | 1.38 ± 1.960 |
| Change at Week 10 | 1.56 ± 2.458 | 1.66 ± 2.155 |
| Change at Week 14 | 1.93 ± 2.762 | 1.88 ± 2.806 |
| Change at Week 22 | 2.40 ± 3.051 | 2.79 ± 3.540 |
| Change at Week 30 | 2.97 ± 3.379 | 3.22 ± 4.338 |
| Change at Week 38 | 3.93 ± 3.698 | 3.70 ± 4.900 |
| Change at Week 46 | 4.40 ± 4.551 | 4.51 ± 4.578 |
| Change at Week 54 | 4.56 ± 4.833 | 4.85 ± 5.033 |
Change from baseline in weight Z-score was reported. Weight z-score expresses how an individual's measured weight compares to the expected weight of a reference population of the same age and sex, standardized using population growth charts. It represents the number of standard deviations (SDs) an individual's weight is above or below the mean of the reference population. Z-score was calculated as: Z-score = (observed value - median value of the reference population) / standard deviation value of reference population. A Z-score of 0 represents the mean of the reference population. A negative Z-score indicates that the observed value is below (lower than) the reference mean, while a positive Z-score indicates that the observed value is above (higher than) the reference mean.
| Z-score | Participants With All Weight Groups Combined: Vedolizumab Low Dose | Participants With All Weight Groups Combined: Vedolizumab High Dose |
|---|---|---|
| Change at Week 2 | 0.080 ± 0.1407 | 0.084 ± 0.1489 |
| Change at Week 6 | 0.161 ± 0.2532 | 0.164 ± 0.2490 |
| Change at Week 10 | 0.227 ± 0.2955 | 0.210 ± 0.2799 |
| Change at Week 14 | 0.269 ± 0.3479 | 0.237 ± 0.3312 |
| Change at Week 22 | 0.325 ± 0.3708 | 0.347 ± 0.3861 |
| Change at Week 30 | 0.410 ± 0.4268 | 0.394 ± 0.4892 |
| Change at Week 38 | 0.519 ± 0.4425 | 0.462 ± 0.5510 |
| Change at Week 46 | 0.585 ± 0.5224 | 0.570 ± 0.5000 |
| Change at Week 54 | 0.609 ± 0.5462 | 0.622 ± 0.5570 |
Change from baseline in height was reported.
| centimeters (cm) | Participants With All Weight Groups Combined: Vedolizumab Low Dose | Participants With All Weight Groups Combined: Vedolizumab High Dose |
|---|---|---|
| Change at Week 2 | 0.20 ± 0.448 | 0.27 ± 0.699 |
| Change at Week 6 | 0.45 ± 0.645 | 0.39 ± 1.051 |
| Change at Week 10 | 0.65 ± 0.866 | 0.85 ± 1.317 |
| Change at Week 14 | 1.08 ± 1.087 | 1.14 ± 1.492 |
| Change at Week 22 | 1.80 ± 1.617 | 1.82 ± 2.007 |
| Change at Week 30 | 2.45 ± 1.996 | 2.59 ± 2.064 |
| Change at Week 38 | 3.30 ± 2.359 | 3.07 ± 2.433 |
| Change at Week 46 | 3.93 ± 2.893 | 3.76 ± 2.748 |
| Change at Week 54 | 4.64 ± 3.274 | 3.99 ± 3.227 |
Change from baseline in linear growth Z-score were reported. Linear growth Z-score is a standardized measure that describes how far a measured height deviates from the median height of a reference population of the same age and sex based on established growth charts. It is expressed in units of standard deviations (SD). Z-score was calculated as: Z-score = (observed value - median value of the reference population) / standard deviation value of reference population. A Z-score of 0 represents the mean of the reference population. A negative Z-score indicates that the observed value is below (lower than) the reference mean, while a positive Z-score indicates that the observed value is above (higher than) the reference mean.
| Z-score | Participants With All Weight Groups Combined: Vedolizumab Low Dose | Participants With All Weight Groups Combined: Vedolizumab High Dose |
|---|---|---|
| Change at Week 2 | 0.033 ± 0.0711 | 0.040 ± 0.1032 |
| Change at Week 6 | 0.072 ± 0.1026 | 0.057 ± 0.1457 |
| Change at Week 10 | 0.106 ± 0.1532 | 0.134 ± 0.2267 |
| Change at Week 14 | 0.175 ± 0.1883 | 0.186 ± 0.2631 |
| Change at Week 22 | 0.290 ± 0.2893 | 0.297 ± 0.3682 |
| Change at Week 30 | 0.389 ± 0.3575 | 0.407 ± 0.3755 |
| Change at Week 38 | 0.537 ± 0.4534 | 0.490 ± 0.4553 |
| Change at Week 46 | 0.629 ± 0.5383 | 0.602 ± 0.5154 |
| Change at Week 54 | 0.754 ± 0.6341 | 0.616 ± 0.5673 |
Tanner stages are used to evaluate growth parameters. They are standardized for age, sex, and pubertal development, with Stage 1 representing the prepubertal stage and Stage 5 representing the fully mature adult stage. It measures Female pubertal development staged by pubic hair development and breast size; male pubertal development staged by size of the genitalia and development of pubic hair. Rated in 5 stages: stage 1 (no development) to 5 (adult-like development in quantity and size). The data reported shows shifts in participants' Tanner stages from baseline to Week 54.
| Participants | Participants With All Weight Groups Combined: Vedolizumab Low Dose | Participants With All Weight Groups Combined: Vedolizumab High Dose |
|---|---|---|
| Male: Genitals — Tanner Stage 1 (Baseline) - Tanner Stage 1 (Week 54) | 4 | 4 |
| Male: Genitals — Tanner Stage 1 (Baseline) - Tanner Stage 2 (Week 54) | 0 | 1 |
| Male: Genitals — Tanner Stage 1 (Baseline) - Tanner Stage 3 (Week 54) | 0 | 0 |
| Male: Genitals — Tanner Stage 1 (Baseline) - Tanner Stage 4 (Week 54) | 0 | 0 |
| Male: Genitals — Tanner Stage 1 (Baseline) - Tanner Stage 5 (Week 54) | 0 | 0 |
| Male: Genitals — Tanner Stage 2 (Baseline) - Tanner Stage 1 (Week 54) | 0 | 1 |
| Male: Genitals — Tanner Stage 2 (Baseline) - Tanner Stage 2 (Week 54) | 1 | 1 |
| Male: Genitals — Tanner Stage 2 (Baseline) - Tanner Stage 3 (Week 54) | 2 | 0 |
| Male: Genitals — Tanner Stage 2 (Baseline) - Tanner Stage 4 (Week 54) | 1 | 0 |
| Male: Genitals — Tanner Stage 2 (Baseline) - Tanner Stage 5 (Week 54) | 0 | 0 |
| Male: Genitals — Tanner Stage 3 (Baseline) - Tanner Stage 1 (Week 54) | 0 | 0 |
| Male: Genitals — Tanner Stage 3 (Baseline) - Tanner Stage 2 (Week 54) | 1 | 1 |
| Male: Genitals — Tanner Stage 3 (Baseline) - Tanner Stage 3 (Week 54) | 0 | 2 |
| Male: Genitals — Tanner Stage 3 (Baseline) - Tanner Stage 4 (Week 54) | 2 | 2 |
| Male: Genitals — Tanner Stage 3 (Baseline) - Tanner Stage 5 (Week 54) | 0 | 0 |
| Male: Genitals — Tanner Stage 4 (Baseline) - Tanner Stage 1 (Week 54) | 0 | 0 |
| Male: Genitals — Tanner Stage 4 (Baseline) - Tanner Stage 2 (Week 54) | 0 | 0 |
| Male: Genitals — Tanner Stage 4 (Baseline) - Tanner Stage 3 (Week 54) | 0 | 0 |
| Male: Genitals — Tanner Stage 4 (Baseline) - Tanner Stage 4 (Week 54) | 1 | 3 |
| Male: Genitals — Tanner Stage 4 (Baseline) - Tanner Stage 5 (Week 54) | 6 | 4 |
| Male: Genitals — Tanner Stage 5 (Baseline) - Tanner Stage 1 (Week 54) | 0 | 0 |
| Male: Genitals — Tanner Stage 5 (Baseline) - Tanner Stage 2 (Week 54) | 0 | 0 |
| Male: Genitals — Tanner Stage 5 (Baseline) - Tanner Stage 3 (Week 54) | 0 | 0 |
| Male: Genitals — Tanner Stage 5 (Baseline) - Tanner Stage 4 (Week 54) | 0 | 0 |
| Male: Genitals — Tanner Stage 5 (Baseline) - Tanner Stage 5 (Week 54) | 3 | 0 |
| Male: Pubic Hair — Tanner Stage 1 (Baseline) - Tanner Stage 1 (Week 54) | 5 | 5 |
| Male: Pubic Hair — Tanner Stage 1 (Baseline) - Tanner Stage 2 (Week 54) | 0 | 1 |
| Male: Pubic Hair — Tanner Stage 1 (Baseline) - Tanner Stage 3 (Week 54) | 0 | 0 |
| Male: Pubic Hair — Tanner Stage 1 (Baseline) - Tanner Stage 4 (Week 54) | 0 | 0 |
| Male: Pubic Hair — Tanner Stage 1 (Baseline) - Tanner Stage 5 (Week 54) | 0 | 0 |
| Male: Pubic Hair — Tanner Stage 2 (Baseline) - Tanner Stage 1 (Week 54) | 0 | 1 |
| Male: Pubic Hair — Tanner Stage 2 (Baseline) - Tanner Stage 2 (Week 54) | 0 | 1 |
| Male: Pubic Hair — Tanner Stage 2 (Baseline) - Tanner Stage 3 (Week 54) | 2 | 0 |
| Male: Pubic Hair — Tanner Stage 2 (Baseline) - Tanner Stage 4 (Week 54) | 1 | 0 |
| Male: Pubic Hair — Tanner Stage 2 (Baseline) - Tanner Stage 5 (Week 54) | 0 | 0 |
| Male: Pubic Hair — Tanner Stage 3 (Baseline) - Tanner Stage 1 (Week 54) | 0 | 0 |
| Male: Pubic Hair — Tanner Stage 3 (Baseline) - Tanner Stage 2 (Week 54) | 1 | 0 |
| Male: Pubic Hair — Tanner Stage 3 (Baseline) - Tanner Stage 3 (Week 54) | 0 | 2 |
| Male: Pubic Hair — Tanner Stage 3 (Baseline) - Tanner Stage 4 (Week 54) | 2 | 2 |
| Male: Pubic Hair — Tanner Stage 3 (Baseline) - Tanner Stage 5 (Week 54) | 0 | 0 |
| Male: Pubic Hair — Tanner Stage 4 (Baseline) - Tanner Stage 1 (Week 54) | 0 | 0 |
| Male: Pubic Hair — Tanner Stage 4 (Baseline) - Tanner Stage 2 (Week 54) | 0 | 0 |
| Male: Pubic Hair — Tanner Stage 4 (Baseline) - Tanner Stage 3 (Week 54) | 0 | 0 |
| Male: Pubic Hair — Tanner Stage 4 (Baseline) - Tanner Stage 4 (Week 54) | 1 | 3 |
| Male: Pubic Hair — Tanner Stage 4 (Baseline) - Tanner Stage 5 (Week 54) | 5 | 4 |
| Male: Pubic Hair — Tanner Stage 5 (Baseline) - Tanner Stage 1 (Week 54) | 0 | 0 |
| Male: Pubic Hair — Tanner Stage 5 (Baseline) - Tanner Stage 2 (Week 54) | 0 | 0 |
| Male: Pubic Hair — Tanner Stage 5 (Baseline) - Tanner Stage 3 (Week 54) | 0 | 0 |
| Male: Pubic Hair — Tanner Stage 5 (Baseline) - Tanner Stage 4 (Week 54) | 0 | 0 |
| Male: Pubic Hair — Tanner Stage 5 (Baseline) - Tanner Stage 5 (Week 54) | 4 | 0 |
| Male: Growth — Tanner Stage 1 (Baseline) - Tanner Stage 1 (Week 54) | 4 | 5 |
| Male: Growth — Tanner Stage 1 (Baseline) - Tanner Stage 2 (Week 54) | 0 | 2 |
| Male: Growth — Tanner Stage 1 (Baseline) - Tanner Stage 3 (Week 54) | 1 | 0 |
| Male: Growth — Tanner Stage 1 (Baseline) - Tanner Stage 4 (Week 54) | 0 | 0 |
| Male: Growth — Tanner Stage 1 (Baseline) - Tanner Stage 5 (Week 54) | 0 | 0 |
| Male: Growth — Tanner Stage 2 (Baseline) - Tanner Stage 1 (Week 54) | 0 | 1 |
| Male: Growth — Tanner Stage 2 (Baseline) - Tanner Stage 2 (Week 54) | 2 | 1 |
| Male: Growth — Tanner Stage 2 (Baseline) - Tanner Stage 3 (Week 54) | 2 | 0 |
| Male: Growth — Tanner Stage 2 (Baseline) - Tanner Stage 4 (Week 54) | 1 | 0 |
| Male: Growth — Tanner Stage 2 (Baseline) - Tanner Stage 5 (Week 54) | 0 | 0 |
| Male: Growth — Tanner Stage 3 (Baseline) - Tanner Stage 1 (Week 54) | 0 | 0 |
| Male: Growth — Tanner Stage 3 (Baseline) - Tanner Stage 2 (Week 54) | 0 | 0 |
| Male: Growth — Tanner Stage 3 (Baseline) - Tanner Stage 3 (Week 54) | 2 | 4 |
| Male: Growth — Tanner Stage 3 (Baseline) - Tanner Stage 4 (Week 54) | 0 | 1 |
| Male: Growth — Tanner Stage 3 (Baseline) - Tanner Stage 5 (Week 54) | 0 | 0 |
| Male: Growth — Tanner Stage 4 (Baseline) - Tanner Stage 1 (Week 54) | 0 | 0 |
| Male: Growth — Tanner Stage 4 (Baseline) - Tanner Stage 2 (Week 54) | 0 | 0 |
| Male: Growth — Tanner Stage 4 (Baseline) - Tanner Stage 3 (Week 54) | 1 | 1 |
| Male: Growth — Tanner Stage 4 (Baseline) - Tanner Stage 4 (Week 54) | 0 | 1 |
| Male: Growth — Tanner Stage 4 (Baseline) - Tanner Stage 5 (Week 54) | 3 | 2 |
| Male: Growth — Tanner Stage 5 (Baseline) - Tanner Stage 1 (Week 54) | 0 | 0 |
| Male: Growth — Tanner Stage 5 (Baseline) - Tanner Stage 2 (Week 54) | 0 | 0 |
| Male: Growth — Tanner Stage 5 (Baseline) - Tanner Stage 3 (Week 54) | 1 | 0 |
| Male: Growth — Tanner Stage 5 (Baseline) - Tanner Stage 4 (Week 54) | 0 | 0 |
| Male: Growth — Tanner Stage 5 (Baseline) - Tanner Stage 5 (Week 54) | 4 | 1 |
| Female: Breast Development — Tanner Stage 1 (Baseline) - Tanner Stage 1 (Week 54) | 5 | 3 |
| Female: Breast Development — Tanner Stage 1 (Baseline) - Tanner Stage 2 (Week 54) | 1 | 3 |
| Female: Breast Development — Tanner Stage 1 (Baseline) - Tanner Stage 3 (Week 54) | 1 | 0 |
| Female: Breast Development — Tanner Stage 1 (Baseline) - Tanner Stage 4 (Week 54) | 0 | 0 |
| Female: Breast Development — Tanner Stage 1 (Baseline) - Tanner Stage 5 (Week 54) | 0 | 0 |
| Female: Breast Development — Tanner Stage 2 (Baseline) - Tanner Stage 1 (Week 54) | 0 | 0 |
| Female: Breast Development — Tanner Stage 2 (Baseline) - Tanner Stage 2 (Week 54) | 0 | 0 |
| Female: Breast Development — Tanner Stage 2 (Baseline) - Tanner Stage 3 (Week 54) | 3 | 1 |
| Female: Breast Development — Tanner Stage 2 (Baseline) - Tanner Stage 4 (Week 54) | 0 | 0 |
| Female: Breast Development — Tanner Stage 2 (Baseline) - Tanner Stage 5 (Week 54) | 1 | 0 |
| Female: Breast Development — Tanner Stage 3 (Baseline) - Tanner Stage 1 (Week 54) | 0 | 0 |
| Female: Breast Development — Tanner Stage 3 (Baseline) - Tanner Stage 2 (Week 54) | 0 | 0 |
| Female: Breast Development — Tanner Stage 3 (Baseline) - Tanner Stage 3 (Week 54) | 4 | 1 |
| Female: Breast Development — Tanner Stage 3 (Baseline) - Tanner Stage 4 (Week 54) | 3 | 3 |
| Female: Breast Development — Tanner Stage 3 (Baseline) - Tanner Stage 5 (Week 54) | 0 | 0 |
| Female: Breast Development — Tanner Stage 4 (Baseline) - Tanner Stage 1 (Week 54) | 0 | 0 |
| Female: Breast Development — Tanner Stage 4 (Baseline) - Tanner Stage 2 (Week 54) | 0 | 0 |
| Female: Breast Development — Tanner Stage 4 (Baseline) - Tanner Stage 3 (Week 54) | 0 | 0 |
| Female: Breast Development — Tanner Stage 4 (Baseline) - Tanner Stage 4 (Week 54) | 1 | 1 |
| Female: Breast Development — Tanner Stage 4 (Baseline) - Tanner Stage 5 (Week 54) | 0 | 2 |
| Female: Breast Development — Tanner Stage 5 (Baseline) - Tanner Stage 1 (Week 54) | 0 | 0 |
| Female: Breast Development — Tanner Stage 5 (Baseline) - Tanner Stage 2 (Week 54) | 0 | 0 |
| Female: Breast Development — Tanner Stage 5 (Baseline) - Tanner Stage 3 (Week 54) | 0 | 1 |
| Female: Breast Development — Tanner Stage 5 (Baseline) - Tanner Stage 4 (Week 54) | 1 | 0 |
| Female: Breast Development — Tanner Stage 5 (Baseline) - Tanner Stage 5 (Week 54) | 2 | 0 |
| Female: Pubic Hair — Tanner Stage 1 (Baseline) - Tanner Stage 1 (Week 54) | 5 | 5 |
| Female: Pubic Hair — Tanner Stage 1 (Baseline) - Tanner Stage 2 (Week 54) | 1 | 2 |
| Female: Pubic Hair — Tanner Stage 1 (Baseline) - Tanner Stage 3 (Week 54) | 1 | 1 |
| Female: Pubic Hair — Tanner Stage 1 (Baseline) - Tanner Stage 4 (Week 54) | 0 | 0 |
| Female: Pubic Hair — Tanner Stage 1 (Baseline) - Tanner Stage 5 (Week 54) | 0 | 0 |
| Female: Pubic Hair — Tanner Stage 2 (Baseline) - Tanner Stage 1 (Week 54) | 0 | 0 |
| Female: Pubic Hair — Tanner Stage 2 (Baseline) - Tanner Stage 2 (Week 54) | 0 | 0 |
| Female: Pubic Hair — Tanner Stage 2 (Baseline) - Tanner Stage 3 (Week 54) | 5 | 0 |
| Female: Pubic Hair — Tanner Stage 2 (Baseline) - Tanner Stage 4 (Week 54) | 0 | 0 |
| Female: Pubic Hair — Tanner Stage 2 (Baseline) - Tanner Stage 5 (Week 54) | 0 | 0 |
| Female: Pubic Hair — Tanner Stage 3 (Baseline) - Tanner Stage 1 (Week 54) | 0 | 0 |
| Female: Pubic Hair — Tanner Stage 3 (Baseline) - Tanner Stage 2 (Week 54) | 0 | 0 |
| Female: Pubic Hair — Tanner Stage 3 (Baseline) - Tanner Stage 3 (Week 54) | 4 | 0 |
| Female: Pubic Hair — Tanner Stage 3 (Baseline) - Tanner Stage 4 (Week 54) | 2 | 3 |
| Female: Pubic Hair — Tanner Stage 3 (Baseline) - Tanner Stage 5 (Week 54) | 0 | 0 |
| Female: Pubic Hair — Tanner Stage 4 (Baseline) - Tanner Stage 1 (Week 54) | 0 | 0 |
| Female: Pubic Hair — Tanner Stage 4 (Baseline) - Tanner Stage 2 (Week 54) | 0 | 0 |
| Female: Pubic Hair — Tanner Stage 4 (Baseline) - Tanner Stage 3 (Week 54) | 0 | 0 |
| Female: Pubic Hair — Tanner Stage 4 (Baseline) - Tanner Stage 4 (Week 54) | 1 | 2 |
| Female: Pubic Hair — Tanner Stage 4 (Baseline) - Tanner Stage 5 (Week 54) | 0 | 2 |
| Female: Pubic Hair — Tanner Stage 5 (Baseline) - Tanner Stage 1 (Week 54) | 0 | 0 |
| Female: Pubic Hair — Tanner Stage 5 (Baseline) - Tanner Stage 2 (Week 54) | 0 | 0 |
| Female: Pubic Hair — Tanner Stage 5 (Baseline) - Tanner Stage 3 (Week 54) | 1 | 1 |
| Female: Pubic Hair — Tanner Stage 5 (Baseline) - Tanner Stage 4 (Week 54) | 0 | 0 |
| Female: Pubic Hair — Tanner Stage 5 (Baseline) - Tanner Stage 5 (Week 54) | 2 | 0 |
| Female: Growth — Tanner Stage 1 (Baseline) - Tanner Stage 1 (Week 54) | 8 | 6 |
| Female: Growth — Tanner Stage 1 (Baseline) - Tanner Stage 2 (Week 54) | 2 | 2 |
| Female: Growth — Tanner Stage 1 (Baseline) - Tanner Stage 3 (Week 54) | 2 | 1 |
| Female: Growth — Tanner Stage 1 (Baseline) - Tanner Stage 4 (Week 54) | 0 | 0 |
| Female: Growth — Tanner Stage 1 (Baseline) - Tanner Stage 5 (Week 54) | 1 | 0 |
| Female: Growth — Tanner Stage 2 (Baseline) - Tanner Stage 1 (Week 54) | 2 | 0 |
| Female: Growth — Tanner Stage 2 (Baseline) - Tanner Stage 2 (Week 54) | 0 | 1 |
| Female: Growth — Tanner Stage 2 (Baseline) - Tanner Stage 3 (Week 54) | 1 | 0 |
| Female: Growth — Tanner Stage 2 (Baseline) - Tanner Stage 4 (Week 54) | 0 | 0 |
| Female: Growth — Tanner Stage 2 (Baseline) - Tanner Stage 5 (Week 54) | 0 | 0 |
| Female: Growth — Tanner Stage 3 (Baseline) - Tanner Stage 1 (Week 54) | 0 | 0 |
| Female: Growth — Tanner Stage 3 (Baseline) - Tanner Stage 2 (Week 54) | 0 | 0 |
| Female: Growth — Tanner Stage 3 (Baseline) - Tanner Stage 3 (Week 54) | 3 | 0 |
| Female: Growth — Tanner Stage 3 (Baseline) - Tanner Stage 4 (Week 54) | 1 | 2 |
| Female: Growth — Tanner Stage 3 (Baseline) - Tanner Stage 5 (Week 54) | 0 | 0 |
| Female: Growth — Tanner Stage 4 (Baseline) - Tanner Stage 1 (Week 54) | 0 | 0 |
| Female: Growth — Tanner Stage 4 (Baseline) - Tanner Stage 2 (Week 54) | 0 | 0 |
| Female: Growth — Tanner Stage 4 (Baseline) - Tanner Stage 3 (Week 54) | 0 | 0 |
| Female: Growth — Tanner Stage 4 (Baseline) - Tanner Stage 4 (Week 54) | 0 | 0 |
| Female: Growth — Tanner Stage 4 (Baseline) - Tanner Stage 5 (Week 54) | 0 | 0 |
| Female: Growth — Tanner Stage 5 (Baseline) - Tanner Stage 1 (Week 54) | 0 | 0 |
| Female: Growth — Tanner Stage 5 (Baseline) - Tanner Stage 2 (Week 54) | 0 | 1 |
| Female: Growth — Tanner Stage 5 (Baseline) - Tanner Stage 3 (Week 54) | 0 | 0 |
| Female: Growth — Tanner Stage 5 (Baseline) - Tanner Stage 4 (Week 54) | 0 | 0 |
| Female: Growth — Tanner Stage 5 (Baseline) - Tanner Stage 5 (Week 54) | 2 | 2 |
Collected over From first dose of study drug up to end of follow up (up to 3.7 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Participants 10 to 15 kg: Vedolizumab 150 mg | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Participants >15 to <30 kg: Vedolizumab 200 mg | 0/27 (0%) | 4/27 (14.8%) | 16/27 (59.3%) |
| Participants >=30 kg: Vedolizumab 300 mg | 0/90 (0%) | 9/90 (10%) | 34/90 (37.8%) |
| Participants With All Weight Groups Combined: Vedolizumab Low Dose | 0/47 (0%) | 3/47 (6.4%) | 28/47 (59.6%) |
| Participants With All Weight Groups Combined: Vedolizumab High Dose | 0/46 (0%) | 5/46 (10.9%) | 22/46 (47.8%) |
| Event | Participants 10 to 15 kg: Vedolizumab 150 mg | Participants >15 to <30 kg: Vedolizumab 200 mg | Participants >=30 kg: Vedolizumab 300 mg | Participants With All Weight Groups Combined: Vedolizumab Low Dose | Participants With All Weight Groups Combined: Vedolizumab High Dose |
|---|---|---|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 0/3 | 2/27 | 5/90 | 0/47 | 2/46 |
| PyrexiaGeneral disorders | 0/3 | 2/27 | 0/90 | 1/47 | 0/46 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/3 | 1/27 | 0/90 | 0/47 | 0/46 |
| Electrolyte imbalanceMetabolism and nutrition disorders | 0/3 | 1/27 | 0/90 | 0/47 | 0/46 |
| Peripheral swellingGeneral disorders | 0/3 | 1/27 | 0/90 | 0/47 | 0/46 |
| Adenovirus infectionInfections and infestations | 0/3 | 0/27 | 0/90 | 0/47 | 1/46 |
| Cytomegalovirus infectionInfections and infestations | 0/3 | 0/27 | 1/90 | 0/47 | 1/46 |
| Idiopathic intracranial hypertensionNervous system disorders | 0/3 | 0/27 | 0/90 | 0/47 | 1/46 |
| AppendicitisInfections and infestations | 0/3 | 0/27 | 0/90 | 1/47 | 0/46 |
| Dermal cystSkin and subcutaneous tissue disorders | 0/3 | 0/27 | 0/90 | 1/47 | 0/46 |
| Event | Participants 10 to 15 kg: Vedolizumab 150 mg | Participants >15 to <30 kg: Vedolizumab 200 mg | Participants >=30 kg: Vedolizumab 300 mg | Participants With All Weight Groups Combined: Vedolizumab Low Dose | Participants With All Weight Groups Combined: Vedolizumab High Dose |
|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/3 | 0/27 | 4/90 | 1/47 | 4/46 |
| Gastroenteritis viralInfections and infestations | 1/3 | 0/27 | 0/90 | 0/47 | 0/46 |
| Oral herpesInfections and infestations | 1/3 | 0/27 | 1/90 | 0/47 | 1/46 |
| ProctalgiaGastrointestinal disorders | 1/3 | 0/27 | 0/90 | 0/47 | 0/46 |
| Rectal prolapseGastrointestinal disorders | 1/3 | 0/27 | 0/90 | 0/47 | 1/46 |
| ThrombocytosisBlood and lymphatic system disorders | 1/3 | 2/27 | 0/90 | 1/47 | 0/46 |
| Upper respiratory tract infectionInfections and infestations | 1/3 | 8/27 | 14/90 | 13/47 | 8/46 |
| Colitis ulcerativeGastrointestinal disorders | 0/3 | 1/27 | 4/90 | 4/47 | 6/46 |
| PyrexiaGeneral disorders | 0/3 | 3/27 | 5/90 | 4/47 | 4/46 |
| DiarrhoeaGastrointestinal disorders | 0/3 | 0/27 | 1/90 | 0/47 | 4/46 |
The intent to treat (ITT) analysis set included all enrolled participants for the induction period, defined by when the informed consent form was obtained, and the participant was determined not to be a screen failure. Participants were not required to receive any dose of vedolizumab to be included in the ITT population.
| Age, Continuous(years) | Participants 10 to 15 kg: Vedolizumab 150 mg | Participants >15 to <30 kg: Vedolizumab 200 mg | Participants >=30 kg: Vedolizumab 300 mg | Total |
|---|---|---|---|---|
| Mean | 2.7 ± 0.58 | 6.2 ± 2.78 | 13.8 ± 2.24 | 11.9 ± 4.2 |
| Sex: Female, Male(Participants) | Participants 10 to 15 kg: Vedolizumab 150 mg | Participants >15 to <30 kg: Vedolizumab 200 mg | Participants >=30 kg: Vedolizumab 300 mg | Total |
|---|---|---|---|---|
| Female | 2 | 14 | 47 | 63 |
| Male | 1 | 13 | 44 | 58 |
| Ethnicity (NIH/OMB)(Participants) | Participants 10 to 15 kg: Vedolizumab 150 mg | Participants >15 to <30 kg: Vedolizumab 200 mg | Participants >=30 kg: Vedolizumab 300 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 2 | 3 |
| Not Hispanic or Latino | 3 | 26 | 89 | 118 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Participants 10 to 15 kg: Vedolizumab 150 mg | Participants >15 to <30 kg: Vedolizumab 200 mg | Participants >=30 kg: Vedolizumab 300 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 12 | 26 | 38 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 0 | 2 |
| White | 3 | 13 | 64 | 80 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Oct 2021 to primary completion in Jul 2025, 44 months.
Results were first posted in Apr 2026, 9 months after primary completion.
Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 44 months is close to that.
Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vedolizumab